SMAD2 and cancer: The effects of halofuginone against bone metastases are consistent with an inhibition of TGF-β signaling in vivo, as shown by the decrease of phosphorylated Smad2/3 in the nuclei of cancer cells, and a subsequent decrease of TGF-β-regulated prometastatic genes in tumor cells.